2018 Highlights by the Numbers | 6 IPOS in 2018

>$800M Aggregate Cash Balance | $623M Aggregate IPO Capital Raised | 3.7 Years Average Time Investment to IPO

Arteaus' galcanezumab approved as Emgality for treatment of chronic migraine
Read More

New Fund | Investing in Accelerating Atlas-Backed Biotech Companies

ATLAS VENTURE ANNOUNCES $250 MILLION OPPORTUNITY FUND
Read the Press Release

$90M SERIES A/B	$100M SERIES B	$65M SERIES 2018
$65M SERIES B	$36M SERIES B	$31M FINANCING

People | Recruiting All-Star Players to our Portfolio

Catherine Stehman-Breen

CMO, Disarm Therapeutics
Atlas EIR

"As an EIR, I've worked with Atlas-founded biotechs pursuing novel therapies for multiple sclerosis and rare muscle diseases and led their clinical development strategy."

Andrew Cheng

CEO, Akero Therapeutics

"Since joining Akero, I've found that the Atlas team and community share invaluable resources that enable a biotech to rapidly advance its clinical and business goals."

Romesh Subramanian

CEO, Dyne Therapeutics
Atlas EIR

"I chose to work with the Atlas team for a second time because of their scientific excellence and dedication to making great medicines for patients."

New Portfolio | Emerging Biotech Startups

$40M SERIES A	$30M SERIES A
$45M SERIES A	$26M SERIES A

Business Development | Collaborating for Success

Replimune + BMS, Regeneron

Replimune entered into strategic collaborations with Regeneron and BMS, which allow Replimune to develop lead program RP1 in combination with Regeneron's cemiplimab and BMS' nivolumab

Read the Press Release

Translate + Sanofi Pasteur

Translate Bio announced an agreement with Sanofi Pasteur potentially valued at up to $850M to develop vaccines for infectious diseases using novel mRNA technology

Read the Press Release

R&D Progress | Advancing Innovative, High-Impact Science

Alex Harding
Meet Alex

Uciane Scarlett
Meet Uciane

Leaders in pharma and Atlas portfolio companies convened in Park City, UT

Featured CF Patient Advocate Kate Rokos shares her story with the LP community

Second annual Science2Startup will be held April 23, 2019 - visit www.science2startup.com for more information

Atlas Emerging Company Analyst Day engaged a curated group of biotech analysts with Atlas portfolio companies

Our portfolio companies are looking for their next great hire

BIOTECH VENTURE DEAL TERMS ARE MORE "STARTUP-FRIENDLY" THAN EVER LIFESCIVC	Read
A HAT TRICK OF CELL AND GENE THERAPY IPOS: AVRO, MAGENTA, AND UNUM LIFESCIVC	Read
FLOAT LIKE A BUTTERFLY: AGILITY IN BIOTECH FROM THE TRENCHES	Read
HURRICANE LANTUS IS CHANGING THE DRUG PRICING DYNAMIC TIMMERMAN REPORT	Read
NEW DIRECTIONS IN ALZHEIMER'S DISEASE RESEARCH AND DEVELOPMENT FROM THE TRENCHES	Read